Hepatitis B Virus Infection

Copyright © 2008 Massachusetts Medical Society. Reports of successful antiviral therapy for chronic hepatitis B virus (HBV) infection appeared three decades ago,1 and during the past de­ cade, progress has accelerated dramatically. Along with progress, however, has come complexity. So much more is known now than at the dawn of the antiviral era about the protean clinical expressions of HBV infection that determining whom, when, and how to treat has become progressively more challenging.

[1]  A. Lok,et al.  When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection? , 2007, Annals of Internal Medicine.

[2]  D. Suh,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2001 .

[3]  R. Perrillo.  Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations , 1990, Hepatology.

[4]  D. Fong,et al.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.

[5]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[6]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[7]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.

[8]  E. Schiff,et al.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.

[9]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[10]  M. Yuen,et al.  The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points , 2007, Annals of Internal Medicine.

[11]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[12]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[13]  W. Yeo,et al.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy , 2006, Hepatology.

[14]  Jean-Michel Pawlotsky,et al.  Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. , 2008, Gastroenterology.

[15]  N. Terrault,et al.  Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.

[16]  R. D. de Man,et al.  Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B , 2004, Hepatology.

[17]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[18]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[20]  J. Stockman,et al.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .

[21]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[22]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[23]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .

[24]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[25]  F. Miselli,et al.  Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. , 2004, Gastroenterology.

[26]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[27]  A. Makris,et al.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.

[28]  M. Buti,et al.  Chronic hepatitis B: a critical appraisal of current approaches to therapy. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[30]  A. Cross,et al.  [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS , 2007 .

[31]  M. Hirsch.  Entecavir surprise. , 2007, New England Journal of Medicine.

[32]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[33]  R. Goldin,et al.  Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. , 2005, Journal of hepatology.

[34]  T. Liang,et al.  Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. , 2007, Gastroenterology.

[35]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[36]  J. Hoofnagle,et al.  Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. , 1993, Gastroenterology.

[37]  E. Schiff,et al.  Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy , 1999, Hepatology.

[38]  J. Dienstag,et al.  Oral antivirals for chronic hepatitis B. , 2007, Clinics in liver disease.

[39]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[40]  T. Wright,et al.  Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy , 2007, Journal of viral hepatitis.

[41]  M. Mohamadnejad.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2006, Archives of Iranian medicine.

[42]  R. Perrillo.  Therapy of hepatitis B — Viral suppression or eradication? , 2006, Hepatology.

[43]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[44]  W P Havens,et al.  Viral hepatitis. , 1970, The Medical clinics of North America.

[45]  J. Dienstag,et al.  Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. , 1999, The Journal of infectious diseases.

[46]  M. Rugge,et al.  Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B , 1986, Hepatology.

[47]  H. Lee,et al.  Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. , 2003, Journal of hepatology.

[48]  R. Malekzadeh,et al.  Reversibility of cirrhosis in chronic hepatitis B. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  S. Hadziyannis,et al.  Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B , 2001 .

[50]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[51]  A. Lok,et al.  Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B , 2004, Journal of viral hepatitis.

[52]  E. Keeffe,et al.  Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  J. Bigby.  Harrison's Principles of Internal Medicine , 1988 .

[54]  E. Schiff,et al.  Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. , 2003, Journal of hepatology.

[55]  S. Takagi,et al.  Natural History , 2019, Nature.

[56]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.

[57]  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999 .

[58]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[59]  A. Bisceglie,et al.  Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .

[60]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[61]  M. Peters,et al.  Viral hepatitis in HIV infection. , 2007, The New England journal of medicine.

[62]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[63]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[64]  S. Locarnini.  Hepatitis B viral resistance: mechanisms and diagnosis. , 2003, Journal of hepatology.

[65]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[66]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[67]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[68]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[69]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[70]  D. Brenner,et al.  Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. , 2001, Journal of hepatology.

[71]  R. Chung,et al.  Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[72]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[73]  N. Bass,et al.  Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. , 2000, Journal of hepatology.

[74]  Lee-Jen Wei,et al.  Cross-Study Analysis of the Relative Efficacies of Oral Antiviral Therapies for Chronic Hepatitis B Infection in Nucleoside-Naive Patients , 2007, Clinical drug investigation.

[75]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[76]  G. Dusheiko.  Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. , 2003, Journal of hepatology.

[77]  M. Washington,et al.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. , 2006, Archives of internal medicine.

[78]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[79]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[80]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[81]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[82]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[83]  H. Janssen,et al.  Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.

[84]  R. Fontana,et al.  Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B , 2002, Liver transplantation.

[85]  A. Lok,et al.  Hepatitis B virus genotypes in the United States: results of a nationwide study. , 2003, Gastroenterology.

[86]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[87]  J. Hoofnagle,et al.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. , 1982, Annals of internal medicine.

[88]  D. Vassilopoulos,et al.  Treatment of HBeAg-negative chronic hepatitis B. , 2003, Seminars in liver disease.

[89]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[90]  J. Hoofnagle,et al.  10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. , 1998, Hepatology.